Vesalio, LLC

Vesalio, LLC is a medical technology company focused on developing innovative devices for treating vascular occlusions, particularly in thrombectomy for stroke and peripheral arterial disease. Founded in 2013 and headquartered in Nashville, US, Vesalio, LLC specializes in medical devices for vascular occlusions. The company has undergone no significant pivots in its business strategy. Its CEO, Steve Rybka, leads the firm which has successfully completed 2 deals, with the latest funding round occurring on June 2, 2021, where they raised USD 5.

00 mn in a Series A round, bringing the total amount raised to USD 5. 00 mn. Vesalio specializes in the development and commercialization of innovative devices aimed at addressing various types of vascular occlusions, particularly in the domains of stroke thrombectomy and peripheral arterial disease. Their core offerings include the NeVa thrombectomy system, which utilizes integrated clot micro-filtration technology to enhance the efficacy of clot removal in stroke patients, and the pVasc mechanical thrombectomy system, designed for the non-surgical removal of occlusions from the peripheral vasculature.

These products are engineered to deliver high first-pass success rates and are particularly beneficial for patients experiencing complex vascular challenges, such as acute limb ischemia and coronary arterial occlusion. The company primarily serves healthcare providers, hospitals, and vascular specialists across Europe and the Middle East, where their products are currently available and utilized in clinical settings. As the company advances its innovations, it aims to expand its presence further into global markets with a focus on improving patient outcomes in vascular healthcare. Vesalio's revenue generation model is primarily anchored in the sale of its medical devices, specifically the NeVa and pVasc systems.

Transactions occur through direct sales to healthcare institutions and partnerships with medical distributors, facilitating the distribution of their products to hospitals and specialty clinics. The company engages in B2B transactions, supplying healthcare providers with their flagship devices that enhance procedural success in thrombectomy procedures. Revenue is derived from the sales of individual devices and possibly supplementary services related to training and support for healthcare professionals using their systems. Following the recent funding round in June 2021, Vesalio, LLC plans to utilize the funds to support the ongoing US IDE stroke study, establish US infrastructure, expand its innovative product portfolio, and scale international business.

The company aims to launch new products designed to enhance their device offerings and plans to expand into additional markets across the US and Europe by the end of 2023.